STOCK TITAN

Ontrak Insider Filing Reveals Near-Total Control & Major Warrant Overhang

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Schedule 13D/A filed for Ontrak, Inc. (OTRK) on 20 June 2025 discloses updated beneficial ownership positions for Terren S. Peizer and three affiliated entities—Acuitas Group Holdings LLC, Acuitas Capital LLC, and Humanitario Capital LLC. The filing is triggered by recent transactions that altered the group’s aggregate economic exposure through common stock, convertible notes and multiple warrant classes.

Key ownership figures

  • Terren S. Peizer: 68,013,532 shares beneficially owned, representing 97.5 % of the 69,793,767 fully-diluted shares the filer deems outstanding.
  • Acuitas Group Holdings LLC: 44,839,793 shares (91.6 % of 48,925,508 shares).
  • Acuitas Capital LLC: 15,055,568 shares (78.1 % of 19,273,416 shares).
  • Humanitario Capital LLC: 23,173,739 shares (92.4 % of 25,086,107 shares).

The majority of the reported shares are not currently outstanding common stock but are issuable under a complex structure of convertible demand notes, a surviving note, and several warrant classes: New Keep-Well Warrants (14.6 million shares), Demand Warrants (15.0 million), Conversion Warrants (7.5 million) and securities issued in a November 2023 private placement (20.9 million).

Implications for investors

  • The filings confirm that Peizer effectively controls Ontrak with near-total voting and dispositive power, limiting outside shareholder influence.
  • The large number of derivative securities indicates significant potential future dilution if the notes are converted and warrants exercised, pressuring per-share metrics.
  • Continued insider financing suggests access to capital, but reliance on a single investor heightens key-person and governance risk.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Filing shows Peizer-led group controls ~98 % of OTRK; heavy warrant overhang poses substantial dilution risk.

The 13D/A quantifies the Peizer group’s dominant position. Because most of the 68 million shares are issuable, the fully-diluted share count balloons far beyond the 4.2 million currently outstanding, implying a >15× dilution factor if every instrument is exercised. While the insider’s willingness to keep funding the company provides short-term liquidity, the mathematics severely constrain upside for minority holders. From a valuation perspective, any model must incorporate the higher share base and the likelihood of continued low-priced conversions around $1.80. With governance effectively in one person’s hands, strategic optionality (M&A, recapitalisations) is high, but so is single-holder risk. Overall, I view the disclosure as neutral for the stock price in the near term but a headwind for long-term equity value.

TL;DR: Near-total insider control raises minority-protection and board-independence concerns.

Owning 90–98 % of every relevant share class, Terren Peizer can unilaterally elect directors, approve mergers, and amend bylaws. Such concentration often leads to reduced oversight and heightened related-party-transaction risk. The multilevel financing structure—demand notes, keep-well warrants, conversion warrants—also enables the insider to dictate capital terms that may not align with minority interests. For governance-focused investors, this filing is a negative signal; oversight mechanisms (e.g., independent board committees) will have limited leverage given Peizer’s voting power.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
Based on 48,925,508 Shares deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of: (i) 4,217,848 Shares issued and outstanding as of May 31, 2025, as disclosed by the Company in the Registration Statement on Form S-1 filed with the SEC on June 17, 2025 ("June 17 Form S-1"); (ii) an aggregate of 14,644,619 Shares underlying the New Keep Well Warrants previously issued to Acuitas in June 2024; (iii) 1,111,112 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Surviving Note previously issued to Acuitas Capital in November 2023 (assuming (1) a conversion price equal to $1.80 per share and (2) any accrued interest thereon is paid in cash); (iv) an aggregate of 6,416,672 Shares issuable to Acuitas Capital (or its designee) upon the conversion of outstanding Demand Notes purchased by Acuitas Capital (assuming, in each case, (1) a conversion price equal to $1.80 per share and (2) any accrued interest thereon is paid in cash); (v) an aggregate of 15,007,473 Shares underlying the Demand Warrants issued to Acuitas in connection with the purchase of Demand Notes pursuant to the Sixth Amendment; and (vi) an aggregate of 7,527,784 Shares underlying the Conversion Warrants issuable to Acuitas Capital (or its designee) (assuming, in each case, (1) a conversion price equal to $1.80 per share and (2) any accrued interest thereon is paid in cash), in each case, as described further in Item 5 below.


SCHEDULE 13D




Comment for Type of Reporting Person:
Based on 19,273,416 Shares deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of: (i) 4,217,848 Shares issued and outstanding as of May 31, 2025, as disclosed by the Company in the June 17 Form S-1; (ii) 1,111,112 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Surviving Note previously issued to Acuitas Capital in November 2023 (assuming (1) a conversion price equal to $1.80 per share and (2) any accrued interest thereon is paid in cash); (iii) an aggregate of 6,416,672 Shares issuable to Acuitas Capital (or its designee) upon the conversion of outstanding Demand Notes purchased by Acuitas Capital (assuming, in each case, (1) a conversion price equal to $1.80 per share and (2) any accrued interest thereon is paid in cash); and (iv) an aggregate of 7,527,784 Shares underlying the Conversion Warrants issuable to Acuitas Capital (or its designee) (assuming, in each case, (1) a conversion price equal to $1.80 per share and (2) any accrued interest thereon is paid in cash), in each case, as described further in Item 5 below.


SCHEDULE 13D




Comment for Type of Reporting Person:
Based on 25,086,107 Shares deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of: (i) 4,217,848 Shares issued and outstanding as of May 31, 2025, as disclosed by the Company in the June 17 Form S-1; and (ii) an aggregate of 20,868,259 Shares underlying the Private Placement Securities previously issued to Humanitario in November 2023, in each case, as described further below in Item 5.


SCHEDULE 13D




Comment for Type of Reporting Person:
Based on 69,793,767 Shares deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of: (i) 4,217,848 Shares issued and outstanding as of May 31, 2025, as disclosed by the Company in the June 17 Form S-1; (ii) an aggregate of 14,644,619 Shares underlying the New Keep Well Warrants previously issued to Acuitas in June 2024; (iii) an aggregate of 20,868,259 Shares underlying the Private Placement Securities previously issued to Humanitario in November 2023; (iv) 1,111,112 Shares issuable to Acuitas Capital (or its designee) upon the conversion of the Surviving Note previously issued to Acuitas Capital in November 2023 (assuming (1) a conversion price equal to $1.80 per share and (2) any accrued interest thereon is paid in cash); (v) an aggregate of 6,416,672 Shares issuable to Acuitas Capital (or its designee) upon the conversion of outstanding Demand Notes purchased by Acuitas Capital (assuming, in each case, (1) a conversion price equal to $1.80 per share and (2) any accrued interest thereon is paid in cash); (vi) an aggregate of 15,007,473 Shares underlying the Demand Warrants issued to Acuitas in connection with the purchase of Demand Notes pursuant to the Sixth Amendment; and (vii) an aggregate of 7,527,784 Shares underlying the Conversion Warrants issuable to Acuitas Capital (or its designee) (assuming, in each case, (1) a conversion price equal to $1.80 per share and (2) any accrued interest thereon is paid in cash), in each case, as described further in Item 5 below.


SCHEDULE 13D


ACUITAS GROUP HOLDINGS, LLC
Signature:/s/ Terren S. Peizer
Name/Title:TERREN S. PEIZER, CHAIRMAN
Date:06/24/2025
ACUITAS CAPITAL LLC
Signature:/s/ Terren S. Peizer
Name/Title:TERREN S. PEIZER, CHAIRMAN
Date:06/24/2025
HUMANITARIO CAPITAL LLC
Signature:/s/ Terren S. Peizer
Name/Title:TERREN S. PEIZER, SOLE MEMBER
Date:06/24/2025
TERREN S. PEIZER
Signature:/s/ Terren S. Peizer
Name/Title:TERREN S. PEIZER
Date:06/24/2025

FAQ

How many Ontrak (OTRK) shares does Terren S. Peizer now control?

The filing shows 68,013,532 shares beneficially owned, representing 97.5 % of the fully-diluted total the filer calculates.

What is the potential dilution from warrants and convertible notes disclosed in the 13D/A?

Approximately 47 million additional shares could be issued through New Keep-Well, Demand and Conversion Warrants plus note conversions.

Why was this Schedule 13D/A filed on 20 June 2025?

A material change in ownership occurred after recent financing transactions, triggering the requirement to amend the prior 13D.

What percentage of Ontrak’s common stock is owned by Acuitas Group Holdings LLC?

Acuitas Group Holdings reports 44,839,793 shares, or 91.6 % of the 48,925,508 shares it deems outstanding.

Does the filing include any earnings or revenue data?

No. The Schedule 13D/A focuses solely on ownership and does not provide earnings information.
Ontrak Inc

OTC:OTRK

View OTRK Stock Overview

OTRK Rankings

OTRK Latest News

OTRK Latest SEC Filings

OTRK Stock Data

2.34M
4.65M
Health Information Services
Services-misc Health & Allied Services, Nec
Link
United States
MIAMI